SLC2A4 and Hyperglycemia: Administration of RA (120–200 mg/kg, 7 days) dose-dependently ameliorated hyperglycemia and insulin resistance and prevented reduction in GLUT4 expression in streptozotocin (STZ)-induced diabetic rats [26].